15 research outputs found
Safety and Efficacy of FIT039 for Verruca Vulgaris: A Placebo-Controlled, Phase I/II Randomized Controlled Trial
TRIAL DESIGN: Human papillomavirus infection causes verruca vulgaris. CDK9 inhibitor FIT039 inhibits DNA virus proliferation in animal models. We conducted a multicenter, single-blind, placebo-controlled, randomized phase I/II clinical trial evaluating the safety and efficacy of FIT039 against verruca vulgaris. METHODS: Target lesions were treated with liquid nitrogen once, and a FIT039 patch or placebo patch was applied for 14 days. The primary endpoint was lesion disappearance. The secondary endpoints were safety and changes in dimension, cross-sectional area, and the number of petechial lesions. RESULTS: A total of 24 participants were randomly allocated to the FIT039 (n = 13, median age, 54 years) and placebo (n = 11, median age, 62 years) groups. Verruca vulgaris did not disappear. FIT039 decreased the dimension to 76% of the initial value on day 29, followed by an increase to 98% on day 57. Placebo showed a monotonic increase to 107% on day 57. Changes in the cross-sectional area and petechiae number were comparable between the groups. CONCLUSIONS: No drug-related adverse reactions occurred. FIT039 efficacy was not determined in this study
Fundamental physics activities with pulsed neutron at J-PARC(BL05)
"Neutron Optics and Physics (NOP/ BL05)" at MLF in J-PARC is a beamline for
studies of fundamental physics. The beamline is divided into three branches so
that different experiments can be performed in parallel. These beam branches
are being used to develop a variety of new projects. We are developing an
experimental project to measure the neutron lifetime with total uncertainty of
1 s (0.1%). The neutron lifetime is an important parameter in elementary
particle and astrophysics. Thus far, the neutron lifetime has been measured by
several groups; however, different values are obtained from different
measurement methods. This experiment is using a method with different sources
of systematic uncertainty than measurements conducted to date. We are also
developing a source of pulsed ultra-cold neutrons (UCNs) produced from a
Doppler shifter are available at the unpolarized beam branch. We are developing
a time focusing device for UCNs, a so called "rebuncher", which can increase
UCN density from a pulsed UCN source. At the low divergence beam branch, an
experiment to search an unknown intermediate force with nanometer range is
performed by measuring the angular dependence of neutron scattering by noble
gases. Finally the beamline is also used for the research and development of
optical elements and detectors. For example, a position sensitive neutron
detector that uses emulsion to achieve sub-micrometer resolution is currently
under development. We have succeeded in detecting cold and ultra-cold neutrons
using the emulsion detector.Comment: 9 pages, 5 figures, Proceedings of International Conference on
Neutron Optics (NOP2017
Utility of a simplified ultrasonography scoring system among patients with rheumatoid arthritis: A multicenter cohort study
ABSTRACT: We aimed to evaluate the utility of a simplified ultrasonography (US) scoring system, which is desired in daily clinical practice, among patients with rheumatoid arthritis (RA) receiving biological/targeted synthetic disease-modifying antirheumatic drugs (DMARDs).A total of 289 Japanese patients with RA who were started on tumor necrosis factor inhibitors, abatacept, tocilizumab, or Janus kinase inhibitors between June 2013 and April 2019 at one of the 15 participating rheumatology centers were reviewed. We performed US assessment of articular synovia over 22 joints among bilateral wrist and finger joints, and the 22-joint (22j)-GS and 22-joint (22j)-PD scores were evaluated as an indicator of US activity using the sum of the GS and PD scores, respectively.The top 6 most affected joints included the bilateral wrist and second/third metacarpophalangeal joints. Therefore, 6-joint (6j)-GS and -PD scores were defined as the sum of the GS and PD scores from the 6 synovial sites over the aforementioned 6 joints, respectively. Although the 22j- or 6j-US scores were significantly correlated with DAS28-ESR or -CRP scores, the correlations were weak. Conversely, 6j-US scores were significantly and strongly correlated with 22j-US scores not only at baseline but also after therapy initiation.Using a multicenter cohort data, our results indicated that a simplified US scoring system could be adequately tolerated during any disease course among patients with RA receiving biological/targeted synthetic DMARDs
The long-term clinical course of chronic eosinophilic pneumonia
Objective The long-term clinical course and prognosis of patients with chronic eosinophilic pneumonia (CEP) including factors predictive of the relapse of CEP have not been fully investigated. The aim of the present study was to investigate these issues. Methods We retrospectively investigated the rate of relapse and prognosis in 73 patients diagnosed as having CEP. Results Systemic corticosteroid therapy was administered at a prednisolone dose of 29.4±7.6 mg/day. During a median follow-up period of 1, 939 days, 27 patients suffered from relapse of CEP. Two patients developed steroid-induced diabetes mellitus, and 1 patient developed pulmonary nontuberculous mycobacteriosis. Five patients died; however, none died of CEP. A history of smoking was the only independent negative risk factor for relapse of CEP [hazard ratio, 0.37 (0.14-0.98)]. Conclusion Patients with CEP frequently relapse. During the follow-up, metabolic and infectious complications under prolonged corticosteroid therapy are problematic. A history of smoking was a negative factor for predicting the risk of CEP relapse
Cubane‐Type [Mo3S4M] Clusters with First‐Row Groups 4–10 Transition‐Metal Halides Supported by C5Me5 Ligands on Molybdenum
A Case of Pneumothorax Complicated by Multiple Large Pulmonary Nodules Due to Mycobacterium Kansasii Infection
We report a rare case of pulmonary infection with Mycobacterium kansasii complicated by pneumothorax and multiple large nodules in both lungs. A 68-year-old man presented with sudden right chest pain and dyspnea. He was diagnosed with pneumothorax on the right side and immediately treated by insertion of a chest tube and drainage. After admission, the pneumothorax was cured, but a high fever continued. A chest x-ray and computed tomography scan showed multiple large nodules with and without cavities in both lungs. We suspected malignant disease, inflammatory granulomatosis, or pneumomycosis and subsequently performed bronchofiberscopy. The results of a transbronchial lung biopsy indicated caceous necrosis surrounded by epithelioid cells, without forming distinct granulomas on histology, and the results of acid-fast bacilli smear tests were positive. Mycobacterium could not be detected by polymerase chain reaction. Because the patient\u27s condition was poor, we started him on anti-Mycobacterium therapy: rifampin, isoniazid, and ethambutol. His condition subsequently improved. Bacterial culture confirmed the presence of M. kansasii, so the antibiotic therapy was continued. The patient\u27s temperature decreased to below 37°C, and the nodules in his lungs reduced in size. In this atypical case of M. kansasii infection, the patient presented with severe symptoms. Bronchofiberscopy enabled prompt diagnosis and early treatment
Nitrogen reduction by the Fe sites of synthetic [Mo₃S₄Fe] cubes
酵素を模倣した金属-硫黄化合物により窒素還元反応を実現 --持続可能社会に寄与するエネルギー変換に向けた第一歩--. 京都大学プレスリリース. 2022-07-07.SharedIt【https://rdcu.be/cQ644】で、出版社版(印刷・ダウンロード不可)の全文を閲覧することができます.A view-only version is available through the SharedIt link【https://rdcu.be/cQ644】Nitrogen (N₂) fixation by nature, which is a crucial process for the supply of bio-available forms of nitrogen, is performed by nitrogenase. This enzyme uses a unique transition-metal–sulfur–carbon cluster as its active-site co-factor ([(R-homocitrate)MoFe₇S₉C], FeMoco), and the sulfur-surrounded iron (Fe) atoms have been postulated to capture and reduce N₂ (refs.). Although there are a few examples of synthetic counterparts of the FeMoco, metal–sulfur cluster, which have shown binding of N₂ (refs.), the reduction of N₂ by any synthetic metal–sulfur cluster or by the extracted form of FeMoco has remained elusive, despite nearly 50 years of research. Here we show that the Fe atoms in our synthetic [Mo₃S₄Fe] cubes can capture a N₂ molecule and catalyse N₂ silylation to form N(SiMe₃)₃ under treatment with excess sodium and trimethylsilyl chloride. These results exemplify the catalytic silylation of N₂ by a synthetic metal–sulfur cluster and demonstrate the N₂-reduction capability of Fe atoms in a sulfur-rich environment, which is reminiscent of the ability of FeMoco to bind and activate N₂
Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan
BACKGROUND: To evaluate the effect of treatment on serum bone biomarkers and explore whether serum bone biomarkers are associated with therapeutic response in rheumatoid arthritis (RA) patients treated with abatacept. METHODS: We enrolled 59 RA patients treated with abatacept from a multicenter, exploratory, short-term, prospective and observational ultrasound cohort study of patients who received biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) therapy. We evaluated the patients’ clinical disease activity and musculoskeletal ultrasound (MSUS) scores. The serum concentrations of five bone biomarkers were evaluated (dickkopf-1 [Dkk-1], sclerostin [SOST], osteocalcin [OC], osteopontin [OPN], and osteoprotegerin [OPG]) by multiplex bead assays at baseline, 3, and 6 months: the change over 6 months was defined as the Δ value. ‘Power Doppler (PD) responder’ was defined as a patient whose Δtotal PD score over 6 months was greater than the median change. RESULTS: Abatacept significantly improved the clinical disease activity and MSUS score over 6 months. Serum OPG was significantly elevated at 6 months after the abatacept introduction (p = 0.016). The ΔSOST and ΔOPG were significantly greater in the PD responders versus the non-PD responders (p = 0.0041 and 0.0073, respectively). The serum Dkk-1 at baseline was significantly lower in the PD responders (n = 30) vs. the non-PD responders (n = 29) (p = 0.026). A multivariate logistic regression analysis showed that the serum Dkk-1 at baseline (odds ratio 0.50, 95% confidence interval [CI] 0.23–0.91, p = 0.043) was an independent predictor of PD responder status. CONCLUSION: Serum levels of bone biomarkers may be useful for predicting RA patients’ therapeutic responses to abatacept. TRIAL REGISTRATION: Name of the registry: Assessment of therapeutic responsiveness by imaging of the joints in patients with rheumatoid arthritis; A observational cohort study Trial registration number: UMIN000012524 Date of registration: 12/9/2013 URL of trial registry record: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000014657 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12891-021-04392-5